Chugai Pharmaceuticals (TYO: 4519) has announced results from the Phase III J-COVACTA study of Actemra (tocilizumab) as a treatment for coronavirus patients with pneumonia.
The data show that after four weeks, 72.9% of people in the single-arm study could be discharged from the hospital.
81.3% improved in at least one category on the 7-Category Ordinal scale, the primary endpoint of the study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze